Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study

References

• Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–8. doi:10.1016/j.ejca.2018.07.005.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. The essential facts and figures of cancer in France. 2019 [accessed 2019 Feb 26]. http://www.e-cancer.fr/Actualites-et-evenements/Actualites/L-Institut-publie-L-essentiel-des-faits-et-chiffres-des-cancers-en-France-edition-2019.
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34. doi:10.3322/caac.21551.
   PubMed Web of Science ®Google Scholar
• Grapatsas K, Leivaditis V, Tsilogianni Z, Haussmann E, Kaplunov V, Dahm M, Zarogoulidis P, Hohenforst-Schmidt W, Tsakiridis K, Foroulis C, et al. Epidemiology, risk factors, symptomatology, TNM classification of non small cell lung cancer. An overview while waiting the 8th TNM classification. Oncomedicine. 2017;2:14–23. doi:10.7150/oncm.17097.
   Google Scholar
• Couraud S, Westeel V, Ranchon F, Toffart A-C, Souquet P-J, Editorial board of the 2019 edition. Non-small cell lung cancer. Auvergne Rhône-Alpes guidelines in thoracic oncology. 2019 update 2019 [accessed 2019 May 29]. https://ressources-aura.fr/wp-content/uploads/2018/12/CBNPC_2019_VDEF.pdf.
   Google Scholar
• Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373:1627–1639. doi:10.1056/NEJMoa1507643.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med. 2015;373:123–135. doi:10.1056/NEJMoa1504627.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, Molina J, Kim J-H, Arvis CD, Ahn M-J. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–1550. doi:10.1016/S0140-6736(15)01281-7.
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, Von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255–265. doi:10.1016/S0140-6736(16)32517-X.
   PubMed Web of Science ®Google Scholar
• Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv192–iv237. doi:10.1093/annonc/mdy275.
   PubMed Web of Science ®Google Scholar
• Reck M, Taylor F, Penrod JR, DeRosa M, Morrissey L, Dastani H, Orsini L, Gralla RJ. Impact of nivolumab versus docetaxel on health-related quality of life and symptoms in patients with advanced squamous non–small cell lung cancer: results from the CheckMate 017 study. J Thorac Oncol. 2018;13:194–204. doi:10.1016/j.jtho.2017.10.029.
   PubMed Web of Science ®Google Scholar
• Reck M, Brahmer J, Bennett B, Taylor F, Penrod JR, DeRosa M, Dastani H, Spigel DR, Gralla RJ. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057. Eur J Cancer. 2018;102:23–30. doi:10.1016/j.ejca.2018.05.005.
   PubMed Web of Science ®Google Scholar
• Euser AM, Zoccali C, Jager KJ, Dekker FW. Cohort studies: prospective versus retrospective. Nephron Clin Pract. 2009;113:c214–7. doi:10.1159/000235241.
   PubMed Web of Science ®Google Scholar
• Molinier O, Audigier-Valette C, Cadranel J, Monnet I, Hureaux J, Hilgers W, Fauchon E, Fabre E, Besse B, OA BP. 17.05 IFCT-1502 CLINIVO: real-life experience with nivolumab in 600 patients (pts) with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol. 2017;12:S1793. doi:10.1016/j.jtho.2017.09.430.
   Google Scholar
• Schouten RD, Muller M, de Gooijer CJ, Baas P, van den Heuvel M. Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands cancer institute. Lung Cancer. 2018;126:210–216. doi:10.1016/j.lungcan.2017.11.012.
   PubMed Web of Science ®Google Scholar
• Crinò L, Bidoli P, Delmonte A, Grossi F, De Marinis F, Ardizzoni A, Vitiello F, Lo Russo G, Parra HS, Cortesi E, et al. Italian cohort of nivolumab expanded access program in squamous non-small cell lung cancer: results from a real-world population. Oncologist. 2019;24:e1165–e71. doi:10.1634/theoncologist.2018-0737.
   PubMed Web of Science ®Google Scholar
• Crinò L, Bronte G, Bidoli P, Cravero P, Minenza E, Cortesi E, Garassino MC, Proto C, Cappuzzo F, Grossi F, et al. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer. 2019;129:35–40. doi:10.1016/j.lungcan.2018.12.025.
   PubMed Web of Science ®Google Scholar
• Krefting F, Basara N, Schutte W, Spath-Schwalbe E, Alt J, Thiel S, Kimmich M, Fischer JR, Kurz S, Griesinger F, et al. Clinical experience of immunotherapy treatment: efficacy and toxicity analysis of the compassionate use program of nivolumab in patients with advanced squamous cell non-small cell lung cancer. Oncol Res Treat. 2019;42:243–255. doi:10.1159/000499321.
   PubMed Web of Science ®Google Scholar
• Grossi F, Crino L, Logroscino A, Canova S, Delmonte A, Melotti B, Proto C, Gelibter A, Cappuzzo F, Turci D, et al. Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. Eur J Cancer. 2018;100:126–134. doi:10.1016/j.ejca.2018.05.015.
   PubMed Web of Science ®Google Scholar
• Brustugun OT, Sprauten M, Helland A. Real-world data on nivolumab treatment of non-small cell lung cancer. Acta Oncol. 2017;56:438–440. doi:10.1080/0284186X.2016.1253865.
   PubMed Web of Science ®Google Scholar
• Montana M, Garcia ME, Ausias N, Jeanpierre M, Meiffren M, Giorgi R, Vanelle P, Barlesi F. Efficacy and safety of nivolumab in patients with non-small cell lung cancer: a retrospective study in clinical practice. J Chemother. 2018;31:1–5.
   PubMed Web of Science ®Google Scholar
• Geier M, Descourt R, Corre R, Léveiller G, Lamy R, Goarant E, Bizec J, Bernier C, Quéré G, Gaye E, et al. Real life second-line nivolumab in advanced non-small cell lung cancer: a French observational multicenter study of 259 patients (ABCT-IMMUNOBZH). Cancer Rep Rev. 2018;2:1–6. doi:10.15761/CRR.1000164.
   Google Scholar
• Areses Manrique MC, Mosquera Martinez J, Garcia Gonzalez J, Afonso Afonso FJ, Lazaro Quintela M, Fernandez Nunez N, Azpitarte Raposeiras C, Amenedo Gancedo M, Santome Couto L, Garcia Campelo MR, et al. Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience. Transl Lung Cancer Res. 2018;7:404–415. doi:10.21037/tlcr.2018.04.03.
   PubMed Web of Science ®Google Scholar
• Merino Almazan M, Duarte Perez JM, Marin Pozo JF, Ortega Granados AL, Muros De Fuentes B, Quesada SP, Gago Sanchez AI, Rodriguez GP, Jurado Garcia JM, Artime Rodriguez-Hermida F, et al. A multicentre observational study of the effectiveness, safety and economic impact of nivolumab on non-small-cell lung cancer in real clinical practice. Int J Clin Pharm. 2019;41:272–279. doi:10.1007/s11096-018-0772-z.
   PubMed Web of Science ®Google Scholar
• Costa FA, Ramos C, Murteira R, Almodovar T, Passos-Coelho JL, Carvalho MI, Costa L, Brito MJ, Ramos S, Ferreira M, et al. The cancer registry as an ally in monitoring treatment effectiveness. Pulmonology. 2019;25:3–8. doi:10.1016/j.pulmoe.2018.05.007.
   PubMed Web of Science ®Google Scholar
• Tournoy KG, Thomeer M, Germonpre P, Derijcke S, De Pauw R, Galdermans D, Govaert K, Govaerts E, Schildermans R, Declercq I, et al. Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals. Lung Cancer. 2018;115:49–55. doi:10.1016/j.lungcan.2017.11.008.
   PubMed Web of Science ®Google Scholar
• Giaj Levra M, Cotte FE, Corre R, Calvet C, Gaudin AF, Penrod JR, Grumberg V, Jouaneton B, Jolivel R, Assie JB, et al. Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis. Lung Cancer. 2019;140:99–106. doi:10.1016/j.lungcan.2019.12.017.
   PubMed Web of Science ®Google Scholar
• De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE–5-a population-based study. Lancet Oncol. 2014;15:23–34. doi:10.1016/S1470-2045(13)70546-1.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. OPDIVO® (Nivolumab) summary of product characteristics. 2019 [accessed Feb 2019 11]. http://www.ema.europa.eu/documents/product-information/opdivo-epar-product-information_en.pdf.
   Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343–346. doi:10.1016/0197-2456(96)00075-X.
   PubMedGoogle Scholar
• Locher C, Debieuvre D, Coëtmeur D, Goupil F, Molinier O, Collon T, Dayen C, Le Treut J, Asselain B, Martin F. Major changes in lung cancer over the last ten years in France: the KBP-CPHG studies. Lung Cancer. 2013;81:32–38. doi:10.1016/j.lungcan.2013.03.001.
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A, Saito R, Maruyama Y, Kawahara M, Ignatius Ou SH. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol. 2010;5:620–630. doi:10.1097/JTO.0b013e3181d2dcd9.
   PubMed Web of Science ®Google Scholar
• Sanchez de Cos J, Sojo GMA, MV M, Perez Calvo MC, MJ V, MH V. Non-small cell lung cancer and silent brain metastasis. Survival and prognostic factors. Lung Cancer. 2009;63:140–145. doi:10.1016/j.lungcan.2008.04.013.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Borghaei H, Ramalingam SS, Horn L, De Castro Carpeno J, Pluzanski A, Burgio MA, Garassino M, Chow LQM, Gettinger S, et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol. 2019;20:1395–1408. doi:10.1016/S1470-2045(19)30407-3.
   PubMed Web of Science ®Google Scholar